Kruthi Doriya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kruthi Doriya has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Devarai Santhosh Kumar
Indian Institute of Technology, Hyderabad, Telangana, India
4 shared publications Devarai Santhosh Kumar
Department of Chemical Engineering Indian Institute of Technology Hyderabad Hyderabad India
3 shared publications- Anup Ashok
Department of Chemical Engineering, B V Raju Institute of Technology, Narsapur, Medak District, India
2 shared publications Bhaskar N. Thorat
2 shared publicationsAbhay V Kotkondawar
Department of Chemistry, Institute of Chemical Technology-Indian Oil Odisha Campus
1 shared publicationAiswarya M. Rajesh
Department of Chemistry, Institute of Chemical Technology-IndianOil Odisha Campus, Bhubaneswar 751013, Odisha, India
1 shared publication
Latest Publications
- Open Access
- 24 July 2026
- Published by Taylor & Francis in Critical Insights in Biotechnology
- Vol. 1 (1)
Biodegradation of polyurethane: exploring consortia dynamics, enzyme-microbe synergy, and comprehensive toxicity analysis
1. Polyurethane (PU) is an indispensable synthetic polymer valued for its versatility across industries including automotive, construction, furniture, and medicine, where it is widely used in foams...
- 24 July 2026
- Published by Taylor & Francis in Critical Insights in Biotechnology
- Vol. 1 (1)
Open AccessBiodegradation of polyurethane: exploring consortia dynamics, enzyme-microbe synergy, and comprehensive toxicity analysis
1. Polyurethane (PU) is an indispensable synthetic polymer valued for its versatility across industries including automotive, construction, furniture, and medicine, where it is widely used in foams...
- Open Access
- 26 January 2025
- Published by Open Exploration Publishing
- Vol. 3, 100887
Combating antibiotic resistance: mechanisms, challenges, and innovative approaches in antibacterial drug development
Antibiotic resistance is a significant threat to public health and drug development, driven largely by the overuse and misuse of antibiotics in medical and agricultural settings. As bacteria adapt to evade current drugs, managing bacterial infections has become increasingly challenging, leading to prolonged illnesses, higher healthcare costs, and increased mortality. This review explores the critical role of antibiotics in fighting infections and the mechanisms that enable bacteria to resist them. Key antibiotics discussed include carvacrol, dalbavancin, quinolones, fluoroquinolones, and zoliflodacin, each with unique actions against bacterial pathogens. Bacteria have evolved complex resistance strategies, such as enzyme production to neutralize drugs, modifying drug targets, and using efflux pumps to remove antibiotics, significantly reducing drug efficacy. Additionally, the review examines the challenges in antibiotic development, including a declining discovery rate of novel drugs due to high costs and regulatory complexities. Innovative approaches, such as structure-based drug design, combination therapies, and new delivery systems, are highlighted for their potential to create compounds with enhanced action against resistant strains. This review provides valuable insights for researchers and developers aiming to combat antibiotic resistance and advance the development of robust antibacterial therapies for future health security.
- 26 January 2025
- Published by Open Exploration Publishing
- Vol. 3, 100887
Open AccessCombating antibiotic resistance: mechanisms, challenges, and innovative approaches in antibacterial drug development
Antibiotic resistance is a significant threat to public health and drug development, driven largely by the overuse and misuse of antibiotics in medical and agricultural settings. As bacteria adapt to evade current drugs, managing bacterial infections has become increasingly challenging, leading to prolonged illnesses, higher healthcare costs, and increased mortality. This review explores the critical role of antibiotics in fighting infections and the mechanisms that enable bacteria to resist them. Key antibiotics discussed include carvacrol, dalbavancin, quinolones, fluoroquinolones, and zoliflodacin, each with unique actions against bacterial pathogens. Bacteria have evolved complex resistance strategies, such as enzyme production to neutralize drugs, modifying drug targets, and using efflux pumps to remove antibiotics, significantly reducing drug efficacy. Additionally, the review examines the challenges in antibiotic development, including a declining discovery rate of novel drugs due to high costs and regulatory complexities. Innovative approaches, such as structure-based drug design, combination therapies, and new delivery systems, are highlighted for their potential to create compounds with enhanced action against resistant strains. This review provides valuable insights for researchers and developers aiming to combat antibiotic resistance and advance the development of robust antibacterial therapies for future health security.
- 2 August 2024
- Published by Elsevier in International Biodeterioration & Biodegradation
- Vol. 194
Indigenous alkaliphiles as an effective tool for bioremediation of bauxite residue (red mud)
- 2 August 2024
- Published by Elsevier in International Biodeterioration & Biodegradation
- Vol. 194
Indigenous alkaliphiles as an effective tool for bioremediation of bauxite residue (red mud)
- 22 August 2022
- Published by Wiley in Journal of Food Processing and Preservation
- Vol. 46 (11)
A systematic review on fruit‐based fermented foods as an approach to improve dietary diversity
- 22 August 2022
- Published by Wiley in Journal of Food Processing and Preservation
- Vol. 46 (11)
A systematic review on fruit‐based fermented foods as an approach to improve dietary diversity
- Open Access
- 5 February 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-10
Microbes Producing L-Asparaginase free of Glutaminase and Urease isolated from Extreme Locations of Antarctic Soil and Moss
L-Asparaginase (L-asparagine aminohydrolase, E.C. 3.5.1.1) has been proven to be competent in treating Acute Lymphoblastic Leukaemia (ALL), which is widely observed in paediatric and adult groups. Currently, clinical L-Asparaginase formulations are derived from bacterial sources such as Escherichia coli and Erwinia chrysanthemi. These formulations when administered to ALL patients lead to several immunological and hypersensitive reactions. Hence, additional purification steps are required to remove toxicity induced by the amalgamation of other enzymes like glutaminase and urease. Production of L-Asparaginase that is free of glutaminase and urease is a major area of research. In this paper, we report the screening and isolation of fungal species collected from the soil and mosses in the Schirmacher Hills, Dronning Maud Land, Antarctica, that produce L-Asparaginase free of glutaminase and urease. A total of 55 isolates were obtained from 33 environmental samples that were tested by conventional plate techniques using Phenol red and Bromothymol blue as indicators. Among the isolated fungi, 30 isolates showed L-Asparaginase free of glutaminase and urease. The L-Asparaginase producing strain Trichosporon asahii IBBLA1, which showed the highest zone index, was then optimized with a Taguchi design. Optimum enzyme activity of 20.57 U mL−1 was obtained at a temperature of 30 °C and pH of 7.0 after 60 hours. Our work suggests that isolation of fungi from extreme environments such as Antarctica may lead to an important advancement in therapeutic applications with fewer side effects.
- 5 February 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-10
Open AccessMicrobes Producing L-Asparaginase free of Glutaminase and Urease isolated from Extreme Locations of Antarctic Soil and Moss
L-Asparaginase (L-asparagine aminohydrolase, E.C. 3.5.1.1) has been proven to be competent in treating Acute Lymphoblastic Leukaemia (ALL), which is widely observed in paediatric and adult groups. Currently, clinical L-Asparaginase formulations are derived from bacterial sources such as Escherichia coli and Erwinia chrysanthemi. These formulations when administered to ALL patients lead to several immunological and hypersensitive reactions. Hence, additional purification steps are required to remove toxicity induced by the amalgamation of other enzymes like glutaminase and urease. Production of L-Asparaginase that is free of glutaminase and urease is a major area of research. In this paper, we report the screening and isolation of fungal species collected from the soil and mosses in the Schirmacher Hills, Dronning Maud Land, Antarctica, that produce L-Asparaginase free of glutaminase and urease. A total of 55 isolates were obtained from 33 environmental samples that were tested by conventional plate techniques using Phenol red and Bromothymol blue as indicators. Among the isolated fungi, 30 isolates showed L-Asparaginase free of glutaminase and urease. The L-Asparaginase producing strain Trichosporon asahii IBBLA1, which showed the highest zone index, was then optimized with a Taguchi design. Optimum enzyme activity of 20.57 U mL−1 was obtained at a temperature of 30 °C and pH of 7.0 after 60 hours. Our work suggests that isolation of fungi from extreme environments such as Antarctica may lead to an important advancement in therapeutic applications with fewer side effects.
- 1 October 2018
- Published by Elsevier in Biochemical Engineering Journal
- Vol. 138, 188-196
Solid state fermentation of mixed substrate for l-asparaginase production using tray and in-house designed rotary bioreactor
- 1 October 2018
- Published by Elsevier in Biochemical Engineering Journal
- Vol. 138, 188-196
Solid state fermentation of mixed substrate for l-asparaginase production using tray and in-house designed rotary bioreactor
- 1 January 2018
- Published by Elsevier in Biocatalysis and Agricultural Biotechnology
- Vol. 13, 244-250
Optimization of solid substrate mixture and process parameters for the production of L-asparaginase and scale-up using tray bioreactor
- 1 January 2018
- Published by Elsevier in Biocatalysis and Agricultural Biotechnology
- Vol. 13, 244-250
Optimization of solid substrate mixture and process parameters for the production of L-asparaginase and scale-up using tray bioreactor
- 1 January 2017
- Published by Elsevier in Biocatalysis and Agricultural Biotechnology
- Vol. 9, 11-18
Design of solid state bioreactor for industrial applications: An overview to conventional bioreactors
- 1 January 2017
- Published by Elsevier in Biocatalysis and Agricultural Biotechnology
- Vol. 9, 11-18
Design of solid state bioreactor for industrial applications: An overview to conventional bioreactors
- Open Access
- 12 November 2016
- Published by Springer Nature in 3 Biotech
- Vol. 6 (2) , 1-10
Isolation and screening of l-asparaginase free of glutaminase and urease from fungal sp.
L-Asparaginase is a chemotherapeutic drug used in the treatment of acute lymphoblastic leukaemia (ALL), a malignant disorder in children. l-Asparaginase helps in removing acrylamide found in fried and baked foods that is carcinogenic in nature. l-Asparaginase is present in plants, animals and microbes. Various microorganisms such as bacteria, yeast and fungi are generally used for the production of l-asparaginase as it is difficult to obtain the same from plants and animals. l-Asparaginase from bacteria causes anaphylaxis and other abnormal sensitive reactions due to low specificity to asparagine. Toxicity and repression caused by bacterial l-asparaginase shifted focus to eukaryotic microorganisms such as fungi to improve the efficacy of l-asparaginase. Clinically available l-asparaginase has glutaminase and urease that may lead to side effects during treatment of ALL. Current work tested 45 fungal strains isolated from soil and agricultural residues. Isolated fungi were tested using conventional plate assay method with two indicator dyes, phenol red and bromothymol blue (BTB), and results were compared. l-Asparaginase activity was measured by cultivating in modified Czapek–Dox medium. Four strains have shown positive result for l-asparaginase production with no urease or glutaminase activity, among these C7 has high enzyme index of 1.57 and l-asparaginase activity of 33.59 U/mL. l-Asparaginase production by C7 was higher with glucose as carbon source and asparagine as nitrogen source. This is the first report focussing on fungi that can synthesize l-asparaginase of the desired specificity. Since the clinical toxicity of l-asparaginase is attributed to glutaminase and urease activity, available evidence indicates variants negative for glutaminase and urease would provide higher therapeutic index than variants positive for glutaminase and urease.
- 12 November 2016
- Published by Springer Nature in 3 Biotech
- Vol. 6 (2) , 1-10
Open AccessIsolation and screening of l-asparaginase free of glutaminase and urease from fungal sp.
L-Asparaginase is a chemotherapeutic drug used in the treatment of acute lymphoblastic leukaemia (ALL), a malignant disorder in children. l-Asparaginase helps in removing acrylamide found in fried and baked foods that is carcinogenic in nature. l-Asparaginase is present in plants, animals and microbes. Various microorganisms such as bacteria, yeast and fungi are generally used for the production of l-asparaginase as it is difficult to obtain the same from plants and animals. l-Asparaginase from bacteria causes anaphylaxis and other abnormal sensitive reactions due to low specificity to asparagine. Toxicity and repression caused by bacterial l-asparaginase shifted focus to eukaryotic microorganisms such as fungi to improve the efficacy of l-asparaginase. Clinically available l-asparaginase has glutaminase and urease that may lead to side effects during treatment of ALL. Current work tested 45 fungal strains isolated from soil and agricultural residues. Isolated fungi were tested using conventional plate assay method with two indicator dyes, phenol red and bromothymol blue (BTB), and results were compared. l-Asparaginase activity was measured by cultivating in modified Czapek–Dox medium. Four strains have shown positive result for l-asparaginase production with no urease or glutaminase activity, among these C7 has high enzyme index of 1.57 and l-asparaginase activity of 33.59 U/mL. l-Asparaginase production by C7 was higher with glucose as carbon source and asparagine as nitrogen source. This is the first report focussing on fungi that can synthesize l-asparaginase of the desired specificity. Since the clinical toxicity of l-asparaginase is attributed to glutaminase and urease activity, available evidence indicates variants negative for glutaminase and urease would provide higher therapeutic index than variants positive for glutaminase and urease.